Micro Cap Alerts

Blog

  • NEW NASDAQ PROFILE: AppTech Payments Corp (APCX)

    AppTech Corp.

    AppTech has 17 patents related to payments, mobile data, and communication

    Management and the board own approximately 13.6% of the outstanding shares

    MasterCard and VISA have signed on and are fully integrated in. (6)

    Hello Everyone,
    The digital payment market is growing at a rapid pace and is expected to surpass $19 trillion by 2026. This is due to the increasing use of smartphones and the internet.(16) In addition, the number of people using digital payment methods is increasing. Digital payments are on the rise as consumers shift away from traditional methods of payment. The future of digital payments looks extremely bright, with more businesses and consumers embracing this convenient and secure way to pay. There are many reasons why digital payments are becoming more popular. For businesses, digital payments can help to reduce costs associated with processing traditional methods of payment, such as credit cards and checks. Digital payments are also more secure than traditional methods, which can help to prevent fraud and other crimes. The massive shift from traditional payments to digital payments could present a tremendous opportunity for technology companies in the Fintech Space. While there are several large-cap financial institutions attempting to gain a foothold in this space, one small-cap company that appears to be extremely well-positioned for this trend is AppTech Payments Corp. (APCX). Through the recently launched Commerse platform, the company has significantly expanded its offerings. Commerse allows businesses to accept payments through credit cards, digital wallets, cryptos, and POS machines, across a wide range of sales channels including physical stores, online, mobile, and social media platforms. The platform also offers additional features such as text-to-pay, buy-now-pay-later (installment payments), crypto payment options, and certain banking capabilities. Currently, businesses have to avail of individual services from various third parties to attain these capabilities.
    • AppTech is a financial technology (fintech) company that just launched a platform (Commerse™) offering digital payment processing solutions, and certain banking capabilities (such as cross border transactions, currency solutions, and installment payment options) to merchants, businesses, and retailers. (18)
    • The global Payments as a Service (PaaS) and Banking as a Service (BaaS) markets are expected to grow from $85B in 2022, to $384B by 2030, reflecting a CAGR of 21%. (18)
    • Since 2013, the company has been generating revenue by offering payment processing solutions (legacy business) so businesses can process credit/debit card transactions.(18)
    • The company supports over 100 small to large merchants, and has partnerships with various payment processing companies to meet their clients’ requirements.(18)
    • Through the recently launched Commerse™ platform, the company has significantly expanded its offerings, by adding features such as text-to-pay, buy-now-pay-later (installment payments), and cry-p-to payment options. Commerse™ also allows businesses to accept payments through credit cards, digital wallets, cry-p-tos, and point-of-sale (POS) machines across a wide range of sales channels, including physical stores, online, mobile, and social media platforms. (18)
    • AppTech’s initial goal is to upgrade and onboard its existing clients to Commerse™, while targeting new clients. AppTech will receive a percentage of their clients’ transaction volume as processing fees. (18)
    • Fundamental Research Corp. believes a key strength of AppTech is its IP, including 17 patents. According to management, their patents have been quoted in 500+ other patents. Fundamental Research Corp. has verified a few, and have confirmed that several large companies (such as Microsoft/NASDAQ:MSFT, AT&T/NYSE:T, and JP Morgan/NYSE:JPM) have cited AppTech’s technology in their patents. Fundamental Research Corp. believes there is a possibility for AppTech to generate licensing revenue from these companies. (18)
    • Upcoming catalysts include onboarding initial clients to Commerse™, and/or potential for licensing agreements. (18)

    Partnership with Large Players

    1. Total Systems Services/Global Payments (NYSE: GPN/MCAP of $32B)
    2. JetPay(NASDAQ:JTPY/MCAPof$79M)
    3. Harbortouch Payments, a subsidiary of Shift4 Payments Inc. (NYSE:FOUR/MCAP of $2.6B)
    4. CynergyData/PriorityPaymentsSystemsGroup
    5. Fidelity National Information Services Inc. (NYSE: FIS/MACAP of $48B)
    6. Cardconnect/Fiserv Inc. (NASDAQ: FISV/MCAP of $63B).
    7. Worldpay from Fidelity National Information Services Inc.


    email this chart printer-friendly formatNo one EVER got rich following the crowd

    During the early 2000s, in the halls of Harvard University, an economic theory around banking software was created. This theory is called the “red ocean, blue ocean”.(7)

    The Red Ocean includes all of the big merchant processors and all the banking software companies that are picking each other apart in price wars in an ocean of big money. That makes for very bloody or red waters.

    The Blue Ocean is where AppTech swims. There’s no blood but there’s $2.5 trillion in liquid cash sloshing around. (2) In fact, they created their own blue ocean. They found a market where money is already being spent – they entered that market with an entirely new solution that’s cheaper, better, and faster.

    The Red Ocean dwellers are left standing in disbelief – they operate on the assumption that it’s not possible to do what AppTech has done.

    Re-Shaping the Future of Finance

    AppTech has created the ONLY single platform that does both sides of the banking and merchant processing in the world – AND it has all the compliance portions built-in. (6)

    AppTech’s channel to market is B2B2C. Their clients are the large digital platforms as well as large brick and mortar store chains already using banking and merchant services.

    Once they set up these clients, the end user is automatically in the process. This includes the Web and Phone/SMS sales.

    The big reason it is going to be hard to beat AppTech – ever – is their patents. They have seventeen impenetrable patents assigned. These patents are powerful and cover any invoicing or sale between a computer and computer, a computer and cellphone, and cellphone and a cellphone. It could be said, everyone in the world might be breaking their patents right now. They have not looked to enforce them…yet.

    Robust Patent Portfolio

    NASDAQ: APCX
    That said, to avoid conflicts many companies reportedly have stated they want to switch over to AppTech’s system when the final platform is released.

    Mobile Commerce Framework

    View Patent 7,693,752 | View Patent 10,600,094

    View Patent 8,554,632 | View Patent 10,621,639

    View Patent 8,799,102 | View Patent 10,846,726

    View Patent 9,436,956 | View Patent 10,846,727

    View Patent 10,102,556 | View Patent 10,909,593

    View Patent 10,127,592 | View Patent 11,107,140

    View Patent 11,354,715

    This newly acquired patent portfolio is focused on the delivery, purchase, or request of any products or services within specific geolocation and time parameters, provided by a consumer’s mobile phone anywhere in the United States. This portfolio houses the patent that protects all advertising on a mobile phone, including in a store’s mobile application.

    System & Method for Delivering Web Content to a Mobile Device

    View Patent 8,073,895 | View Assignment for Patent 8,073,895

    View Patent 8,572,166 | View Assignment for Patent 8,572,166

    These patents allow companies to send URLs in text messages. They are responsible for helping to create the industry protocol known as Wireless Access Protocol (WAP) Push. WAP is very commonly used when you receive a text message with a link to download content or an application to your mobile phone.

    Mobile-to-Mobile Payment System & Method

    View Patent 8,369,828 | View Assignment for Patent 8,369,828

    This patent was developed for moving money from cell phone to cell phone, person to person, or person to business. We believe it sparked the creation of the P2P (Peer to Peer) Payments industry by allowing users to move money by text message, click, tap, or scan.

    Computer to Mobile Two-Way Chat System & Method

    View Patent 8,315,184 | View Assignment for Patent 8,315,184

    This patent allows for communication from a computer to a mobile phone device via SMS text messaging. This technology is mostly used in social media messenger apps or chat features. When chatting with your friends on your favorite platform, the messages are not moving from cell phone to cell phone. Rather, the messages you send through your phone are sent to the app’s computer, processed, and then routed to the receiver’s mobile device.

    This Company Is Set to Become the Next Giant in the Explosive “Fintech Boom”

    According to a report by JPMorgan, by 2025, widespread adoption and greater use of digital financial services could increase the gross domestic products (GDP) of all emerging economies by 6%, or $3.7 trillion, creating 95 million new jobs. (14)

    This potential is already being realized. Today there are at least six payments and fintech
    unicorns — i.e., startups valued greater than $1 billion — in Africa alone. (14)

    Designed and built from the ground up to be a single solution.

    The platform was envisioned to be for everything from receiving money to all the banking services. They set out to create the ONLY single platform that does both sides of the banking and merchant processing in the world.

    Today’s systems require a ton of programming using the current patchwork solutions. This is because the systems in place were designed before all these new channels (SMS, Web, etc.) to the consumer ever existed.

    With today’s systems, the databases are all talking to each other, and all the systems are intertwined – if you make a change in one place, who knows what else is going to get affected?

    Cheaper. Faster. Better.

    With AppTech, integration fees are lower and the cost to create and maintain a great user experience between all the sales channels. In-store, online, phone etc. is 25% the cost of upgrading or developer costs.

    The bottom line is the integration of the AppTech’s solution in a large enterprise is millions of dollars cheaper and hundreds of thousands cheaper in a midsized company.

    MANAGEMENT

    Luke D’Angelo – Chairman, CEO, CIO, Director

    Mr. D’Angelo has been the Chairman of the Board since 2013, Chief Executive Officer since December 2019. Mr. D’Angelo has over 25 years of experience in real estate, investment banking, venture capital, and commercial operations. In 2006, he founded a merchant services company, Transcendent One, Inc. In 2009, Mr. D’Angelo founded TransTech One, LLC, a subsidiary to Transcendent One, Inc., which is focused on the bill payment and technology industries.

    Gary Wachs – CFO, Treasurer, Director

    Mr. Wachs is a director since 2013 and Chief Financial Officer since 2013. Mr. Wachs is a Certified Public Accountant with experience in high-level accounting, Finance, and tax. Mr. Wachs served as Managing Partner of Blake and Shaffer, a Certified Public Accounting firm, and has been a Managing Member of Blake and Wachs CPA, LTD (formerly Blake and Shaffer) since 1997.

    Virgil Llapitan – President

    Mr. Llapitan has experience in the banking industry. In 1989, he founded his own independent insurance agency and transitioned into the merchant service industry in 2004. There, he developed and marketed the original ACH Payment Processing systems for online merchants as the Chairman, COO, and Director of HIMC Corp. Mr. Llapitan also served as a Universal Banker II for Ameris Bank and Bank of America and Director of Sales for merchant services for Transcendent One.

    Ben Jenkins – Chief Technology Officer

    Mr. Jenkins is a start-up Founder, Chief Executive Officer, and software innovator who has developed new business lines for large corporations and technology start- ups in the last 20 years. He played a key role in developing the payment infrastructure (PayFac) now responsible for processing billions of dollars annually in non-profit donations. Mr. Jenkins also started a near-shore cross-border software innovation and development company in Mexico while continuing to serve as a software and payment consultant for large companies and private equity firms.

    Chad Nelley – Chief Operating Officer

    Mr. Nelley is a business executive for start-ups to Fortune 500 companies with over 25 years of experience in sales, marketing, customer success, information technology, project management, finance, human resources, business intelligence, organizational development, procurement, legal, retail distribution, fulfillment & logistics, and real estate and facilities.

    Kaylei Wright – Chief of Staff

    Upon joining AppTech in 2018, Ms. Wright developed the initial branding and led efforts within the investment community to deliver a successful IPO and Nasdaq listing. She continues to work hand-in-hand with marketing and organizational leadership to curate, define, and shape messaging suited for investors and the general market.

    Marc Evans – Corporate Secretary

    Mr. Evans has worked with AppTech since November 11, 2013 an an Associate and a Director of Business Development. He was a partner at an independent insurance agency and was licensed in property & casualty and life & health insurance for 13 years. During that time, he sat on the agent advisory & technology committee at Mercury Insurance Group.

    SINCERELY

    DISCLAIMER

    THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
    OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, LIFEWATER MEDIA, LLC.  FOR A ONE DAY APCX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

    __________

    Source 1: https://www.mckinsey.com/cn/our-insights/our-insights/seven-technologies-shaping-the-future-of-fintech

    Source 2: https://www.businesswire.com/news/home/20211124006042/en/Global-Digital-Payment-Market-Report-2021-Transactions-Worth-7-Trillion-is-Expected-to-Shift-from-Cash-to-Card-and-Digital-Payments-by-2023—Forecast-to-2028—ResearchAndMarkets.com

    Source 3: https://www.digitaltransactions.net/consumers-say-friction-is-a-leading-cause-of-late-bill-payments-especially-online/

    Source 4: https://www.marketingdive.com/news/brands-could-lose-fickle-gen-zers-over-poor-digital-experiences/598522/

    Source 5: https://www.paymentsjournal.com/community-banks-embrace-third-party-platforms-to-empower-growth/

    Source 6: https://apptechcorp.com/digital-banking/

    Source 7: https://www.clearpointstrategy.com/blue-ocean-strategy/

    Source 8: https://www2.deloitte.com/us/en/pages/finance-transformation/articles/finance-digital-transformation-for-cfos.html

    Source 9: https://www.macrotrends.net/stocks/charts/AMZN/amazon/shares-outstanding

    Source 10: https://tinyurl.com/3pb5jpyh

    Source 11: https://tinyurl.com/ycxmv76j

    Source 12: https://tinyurl.com/2p988yvf

    Source 13: https://www.prnewswire.com/news-releases/global-payment-gateway-market-anticipated-to-garner-a-revenue-of-67-434-4-million-by-2028–growing-at-a-cagr-of-16-6-from-2021-2028–exclusive-report-223-pages-by-research-dive-301391554.html
    Source 14: https://www.jpmorgan.com/content/dam/jpm/treasury-services/documents/jpm-payments-are-eating-the-world.pdf

    Source 15: https://apptechcorp.com/company/#intellectualProperty

    Source 16: https://www.globenewswire.com/news-release/2022/09/19/2518187/0/en/With-24-4-CAGR-Digital-Payment-Market-Size-worth-USD-19-89-Trillion-in-2026.html

    Source 17: https://journey.ct.events/view/a1bdc8ca-df90-45ae-9fd4-97a4cb02b7cc

    Source 18: Source 18: https://22007752.fs1.hubspotusercontent-na1.net/hubfs/22007752/Apptech%20-%20Nov%202022%20-%20Initiating.pdf?utm_campaign=us_apcx&utm_source=apcx_report

    Source 19: https://www.barchart.com/stocks/quotes/APCX/price-history/historical

    Source 20: https://infinios.com/wp-content/uploads/2021/08/finance-e1614679295359-p3mcmm82d3fkmoh3qq8txmwofxgwrcggm5da3gdy68.jpg

    Source 21: https://www.forbes.com/advisor/wp-content/uploads/2020/08/getty_what_is_fintech_080220pm_jpg_yvtZYBW2.jpg

  • NEW NASDAQ PROFILE: BioSig Technologies (BSGM)

    BioSig Technologies, Inc.

    _______

    OUR NEW PROFILE IS:   (NASDAQ: BSGM)

    BIOSIG SEES POSITIVE MOMENTUM FROM SALES PIPELINE GROWTH

    COMPLETION OF MORE THAN 2500 PROCEDURES

    SUBSTANTIAL AND GROWING IP PATENT PORTFOLIO

    __________________

    DOWNLOAD THE FACT SHEET HERE

    GET THE INVESTOR PRESENTATION HERE


    __________________________________

    Hello Everyone,

    We have Nasdaq profile that  we want to bring to your attention for today.

    This next one has several catalysts in play right now at these levels as well as major bounce potential sitting under .50 right now.

    Pull up BSGM immediately for today’s session.  

    BSGM is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. With the global EP market projected to reach $10.1B in 2024 with a 11.3% growth rate, BioSig has commenced a targeted commercial release of its PURE EPTM System, generating its first commercial sale in December 2020. The Company’s first product is a computerized system designed to reveal the full range of cardiac signals and to provide physicians with signal clarity during procedures performed to address cardiac arrhythmias. The PURE EPTM System received FDA 510(k) clearance in August 2018. Physicians using BioSig’s PURE EPTM System have successfully completed over 1,700 patient cases to date. Systems are currently installed at multiple locations, including Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic’s Florida, Minnesota and Arizona campuses, Massachusetts General Hospital, the University of Pennsylvania, Deborah Heart and Lung Center, and Houston Methodist.

    page1image3269523504

    BIOSIG EXECUTES PURCHASE AGREEMENT WITH METHODIST HOSPITAL, SAN ANTONIO AND EXPANDS CUSTOMER BASE

    LEADING MEDICAL CENTER IN SAN ANTONIO ACQUIRES BIOSIG’S NOVEL DIGITAL SIGNAL PROCESSING TECHNOLOGY FOR ARRHYTHMIA CARE

    Westport, CT, Oct. 07, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced that San Antonio Methodist Hospital has acquired the PURE EP™ System.

    The acquisition, one of many in the pipeline, reaffirms the continued expansion of BioSig’s U.S. footprint and customer base.

    “As we continue to advance the national commercial rollout of the PURE EP™ System, we are thrilled to introduce our technology to Methodist Hospital in San Antonio,” said Gray Fleming, Chief Commercial Officer, BioSig Technologies, Inc. “We believe that the PURE EP™ System enhances EP lab infrastructure by integrating with existing workflows and delivers critical signals of interest that are not visible on conventional systems.”

    “PURE EP™ delivers great value to our lab across many different types of ablations. By uncovering new levels of clarity of intracardiac signals, PURE EP™ opens doors to the benefits of signal processing in the digital domain,” commented David N. Pederson, MD, Clinical Cardiac Electrophysiologist, Methodist Hospital, San Antonio, TX.

    About Methodist Healthcare

    Methodist Healthcare is recognized as a leading healthcare provider in South Texas, offering an outstanding selection of doctors, healthcare professionals, equipment and health services. The hospital belongs to a network of hospitals in the greater San Antonio area, including nine acute care facilities: Methodist Hospital, Methodist Children’s Hospital, Methodist Hospital Metropolitan, Methodist Hospital Northeast, Methodist Hospital Atascosa, Methodist Hospital Specialty and Transplant, Methodist Hospital Stone Oak and Methodist Hospital Texsan.

    ________

    ACHIEVEMENTS

    • Announced Evaluation Agreement with Cleveland Clinic
    • Surpassed 2,500 procedures
    • Announced 49 allowed/ issued design and utility patents
    • Appointed John Sieckhaus as Chief Operating Officer
    • Appointed Gray Fleming as Chief Commercial Officer
    • Clinical data acquired by PURE EPTM published in the Journal of Cardiovascular Electrophysiology
    • Selected Plexus Corp. as its manufacturing partner
    • Announced medical device industry leader to its board of directors
    • Unblinding of clinical data from PURE EPTM 2.0 Study showed signal superiority to standard of care
    • Achieved first commercial sales at TCAI and various Mayo Clinic sites

    INVESTMENT HIGHLIGHTS

    • World class commercial team
    • Achieved first revenues
    • Conducted First Clinical Trial with PURE EPTM System
    • Significant Insider Ownership
    • 10-year Strategic Collaboration with Mayo Clinic
    • IP Strategy Led by Sherpa Technology Group and Sterne Kessler Goldstein & Fox. — 49 allowed/issued design and utility patents
    • FDA clearance achieved
    • Proven Management Team and Board of Directors
    • Global and Growing Addressable Market
    • Operates Within Rapidly Emerging Field of Bioelectronic Medicine
    • High-Growth Sector Earns Innovation Premium, Aggressive M&A

    BSGM has made tremendous strides in the placement of their flagship product, PURE EP™ System in clinics across the country this year and has begun to generate revenues, $325K over Q1 and Q2 and I anticipate Q3 results soon.

    In the past two weeks, the share price has crossed the 20 day SMA of $2.90 and the 50 SMA of $2.84 while fast closing in on the 200 SMA of $3.63. While this movement indicates the shares are trending, it may also indicate a near term breakout. Remember the 52-week high is $6.14/share. This is the momentum in company valuation we mentioned above.

    The company’s flagship PURE EP™ System is an advanced monitoring system currently used primarily for cardiac ablation procedures in patients with AFIB (atrial fibrillation) a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. The PURE EP™ System is an FDA 510(k) cleared non-invasive class II device.  BSGM just installed a PURE EP™ System for an evaluation at the HCA Healthcare-operated Medical City Heart Hospital in Dallas, TX. This is the Company’s 17th installation. To date, over 71 physicians have completed over 1600 patient cases with the PURE EP™ System.

    page1image3176916192

    In 2020 the number of patient cases was only 425.

    Clinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. I want to note that BSGM has a long-term relationship with the Mayo Clinic in the development of the PURE EP™ System.

    Last month BSGM signed a manufacturing and professional services agreement with Plexus Corp. (PLXS). Under the terms of the newly reached agreement, Plexus will bring to market the PURE EP™ System, the Company’s signal processing technology for arrhythmia care, and develop a new product pipeline for BioSig’s subsidiary NeuroClear Technologies, Inc. The signing of this manufacturing agreementis yet another potential catalyst in the near-term growth coming for BSGM.

    BSGM maintains a small share structure with 34.9M shares outstanding and 30.4M shares in the public float. The company’s last reported balance sheet at the end of June 2021, indicated zero debt and cash of $15.5M.

    NEUROCLEAR

    NOVEL ENG PLATFORM TECHNOLOGY

    Our technology aims to address technological deficiencies present in the current electroneurogram recording systems through high-speed recording of biomedical signals, the ability to preserve valuable clinical information and optimization of therapy delivery through closed feedback loop.

    Our first product focuses on improving safety and efficacy of renal denervation procedures.

    INTRODUCING N-SENSE

    • Multi-channel hardware designed to sense & stimulate nerves.
    • Simultaneous stimulation and measure for optimal closed loop feedback system.
    • Aid in targeting nerve location.
    • Algorithms tailored to specific applications.
    • Assess nerve for hyperactivity.
    • Catheter-agnostic interface.

    PARTNERSHIPS

    We have partnerships with some of the most distinguished organizations and experts in the fields of electrophysiology, intellectual property (IP) strategy, and technology development.

    In 2017 we signed a ground-breaking 10-year strategic collaboration with experts at Mayo Clinic to both develop advanced clinical features of the PURE EP™ System and explore new disease areas and applications. We expect our collaboration to result in joint patent filings and licensing opportunities. Our research program with Mayo Clinic is run under the leadership of Samuel J. Asirvatham, M.D., Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory.

    We have worked closely with leading patent experts to develop a robust IP strategy. Our IP strategic advisor – Sherpa Technology Group (STG) – is one of the best in the field, working at the intersection of business, technology, and intellectual property. Our patent attorneys, Sterne, Kessler, Goldstein & Fox, are equally distinguished and have been on the cutting edge of IP law for four decades.

    We also have a technology development partnership with Plexus Corp. [Nasdaq: PLXS]. Their engineering and manufacturing capabilities and outstanding expertise in building complex medical devices make Plexus a foundational cornerstone to support BioSig’s growth objectives now and well into the future.

    Mayo ClinicSherpa Technology GroupSterne, Kessler, Goldstein & FoxPlexus Corp.

    KEY GROWTH DRIVERS

    1. 1)  Advanced Technology — The non-invasive PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology EP procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. The PURE EP System aims to minimize noise and artifacts, and acquire high- fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and ablation procedures.
    2. 2)  Market Opportunity — 2019 DRG Medtech 360 Report states the global EP device market is expected to exceed more than US $10.1 billion by 2024 and is growing at a compound annual growth rate (CAGR) of 11.3%. The Company also operates within the rapidly emerging field of bioelectronic medicine, estimated at $25.11 billion in 2020 with projected annual growth of 10.27%.
    3. 3)  KOL Support — PURE EP has been used and valued by many of the industry’s leading electrophysiology physicians, including Dr. Andrea Natale of Texas Cardiac Arrhythmia Institute, and Dr. G. Joseph Gallinghouse. The Company achieved proof of concept validation through UCLA, and has performed numerous pre-clinical studies at Mayo Clinic, MN under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory.

    BIOELECTRONIC MEDICINE

    Bioelectronic medicine is a rapidly growing field of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a range of diseases. The field represents not just a narrow category of medical devices, but an entire approach to detecting and treating disease – using electrical pulses and the body’s own mechanisms as an adjunct or alternative to drugs and medical procedures.

    Bioelectronic medicine applications aim to deliver treatment breakthroughs for many diseases that currently have a high level of unmet need. Researchers and innovators are exploring the field’s applications across various disease areas and disciplines, including neurology, auto-immune diseases, diabetes, arthritis, hypertension, pain management, cancer, and others. This wide range of applications sets bioelectronic medicine apart and indicates its immense potential.

    We know we’re not alone in embracing a future with bioelectronic medicine. The field is making rapid strides, but this is just the beginning of what’s possible. That’s why we helped create the Alliance for Advancing Bioelectronic Medicine, an independent network of professionals dedicated to innovation at the intersection of healthcare and technology. We strive to develop this community with a common goal of realizing the field’s full potential.

    Bioelectronic medicine is already a diverse, $20 billion market. It includes both familiar devices, such as pacemakers, as well as emerging technologies, such as vagus nerve stimulators and implantable neurostimulators. These exciting new segments are proliferating and attracting interest and investment from major players in technology and healthcare, such as Verily Life Sciences, Medtronic, and Johnson & Johnson.

    As the field continues to develop, we believe our unique technology can play a critical enabling role. By providing more precise biomedical signals, our advanced signal processing capabilities can help clinicians better understand and change patterns to treat, or even prevent diseases.

    BIOSIG SIGNS MASTER RESEARCH AGREEMENT WITH CLEVELAND CLINIC TO EXPLORE EXPANDED APPLICATIONS FOR ITS DIGITAL SIGNAL PROCESSING TECHNOLOGY

    Westport, CT, Oct. 24, 2022 (GLOBE NEWSWIRE) —

    • Medical Center of Excellence to leverage the Company’s PURE EP™ System to further its research and educational objectives as a leader in cardiac electrophysiology
    • Clinical investigations conducted by Cleveland Clinic could expand clinical parameters of BioSig’s digital signal processing technology for arrhythmia care

    BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced that it will sponsor a research agreement with Cleveland Clinic Foundation (CCF) to investigate expanded clinical applications for the intracardiac signals acquired by its PURE EP™ System.

    Under the terms of the research agreement, Cleveland Clinic will conduct physician initiated scientific research investigating PURE EP™’s potential to address common limitations of signal processing and signal use expansion during— but not limited to— electrophysiology ablation procedures. Results from this research could elucidate new clinical workflow methods impacting the ablation process for numerous arrhythmia types.

    The Company has selected Cleveland Clinic, a leading medical center of excellence, based on their world-class physician faculty, research competency, and mutual interest in leveraging digital signal processing technology to further advance the field of cardiac electrophysiology.

    “As a non-profit, research, education, and healthcare institution, Cleveland Clinic has a long legacy of innovation in cardiovascular disease, and specifically in the field of electrophysiology. At BioSig, we embody their commitment to clinical discovery and ensuring that optimal treatments are made available to patients with efficiency and efficacy,” said Gray Fleming, Chief Commercialization Officer, BioSig Technologies, Inc. “We are honored to align ourselves with Cleveland Clinic’s expertise as we discover new ways to positively impact procedural workflows by leveraging digital signal processing technology.”

    BioSig’s PURE EP™ System is currently under evaluation at both Main and Fairview campuses of Cleveland Clinic’s Heart, Vascular & Thoracic Institute.

    About Cleveland Clinic

    Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. As a leader in arrhythmia treatment and diagnosis, Cleveland Clinic medical centers include state-of-the-art electrophysiology laboratories, world-class physicians and researchers, and the latest cutting-edge technologies and protocols deployed for the treatment of heart abnormalities. To learn more, visit clevelandclinic.org.

    NEWS

    BIOSIG SIGNS MASTER RESEARCH AGREEMENT WITH CLEVELAND CLINIC TO EXPLORE EXPANDED APPLICATIONS FOR ITS DIGITAL SIGNAL PROCESSING TECHNOLOGY

    Kenneth L. Londoner, MBA

    KENNETH L. LONDONER, MBA

    Founder, Chief Executive Officer, Chairman, and Director

    Mr. Londoner is a capital markets and capital architecture expert and a senior life science executive. Having started his career as a research analyst for J. & W. Seligman & Co., Inc., a leading institutional money management firm in New York City, NY, he quickly found himself at the forefront of the biotech industry in the early 1990s, leading him to manage $3.5 billion in mutual and pension funds and international assets.

    His passion for medical innovation led him to co-found, govern and bring to the public market a number of life science companies, including BioSig Technologies, Inc. [Nasdaq:BSGM]. Working in close collaboration with key opinion leaders in electrophysiology, BioSig aims to improve the outcomes of cardiac ablations for the treatment of arrhythmias through novel technological solutions developed by the company, and further apply its core competency in advanced biomedical signal processing and analysis to other areas of medicine.

    His prior experience in recognizing the early potential of biotech led Londoner to form the Alliance for Advancing Bioelectronic Medicine, an independent non-profit network of professionals dedicated to innovation at the intersection of healthcare and technology. The Alliance aims to increase awareness of bioelectronic medicine and build a platform for collaboration among stakeholders. Over the last decade, Londoner formed top level relationships with a number of medical centers of excellence such as Mayo Clinic, NYU Langone Hospital and UCLA, as well as other stakeholders, including investment communities, intellectual property experts and supply chain partners.

    Steve Chaussy

    STEVE CHAUSSY

    Chief Financial Officer

    Mr. Chaussy has served as Chief Financial Officer of BioSig Technologies, Inc., since May of 2011, making him one of the Company’s most veteran executives. He brings an impressive array of professional experiences, detailed protocols, and an adept understanding of the financial operations of public companies.

    Mr. Chaussy has an extensive entrepreneurial growth and development background from working for Penske Truck Leasing Co., L.P., a Penske Corporation subsidiary, where his improvements of management and reporting tools allowed the Company to double in size. Since 2005, Mr. Chaussy has been the sole proprietor of Anna & Co., Inc., a consulting company that offers services to small publicly traded companies. Anna & Co., Inc. provides general financial and accounting services, emphasizing SEC reporting and compliance, to companies that lack sufficient resources to hire full-time employees to offer such services. From 2001 to 2005, Mr. Chaussy provided services as both a Chief Financial Officer and a consultant to small publicly traded companies. Before 2001, Mr. Chaussy served as the chief financial officer for a large private distribution and wholesaling Company, where he gained international experience.

    Mr. Chaussy is a graduate of Virginia Polytechnic Institute and State University and is a licensed, certified public accountant in Virginia, California, and Florida.

    Natasha Drapeau

    NATASHA DRAPEAU

    Executive Vice President

    Natasha Drapeau has been with BioSig Technologies, Inc. since May of 2017 and is primarily responsible for leading Company operations. Based in Geneva, Switzerland, Ms. Drapeau is BioSig’s primary executive for future European operations. She works closely with the Board of Directors and strategic partners, including medical centers of excellence and IP advisors. Ms. Drapeau serves as President at NeuroClear, Inc., Executive Vice President at BioSig Technologies, Inc., and is a founding member of the Alliance for Advancing Bioelectronic Medicine.

    Ms. Drapeau brings over 18 years of international business development experience, including more than nine years at IG Group Plc, a leading British FTSE 250 financial services company. While working for IG, she was responsible for the Group’s global business development, including a worldwide rebranding and business support to 16 international offices in Europe, South Africa, Singapore, and Australia.

    Mrs. Drapeau holds two MSc degrees with honors in Management and German from Samara Academy of Economics, as well as a Business, International Relations, and Political Economy degree from The London School of Economics. Mrs. Drapeau is a member of the Institute of Directors in the United Kingdom.

    Brenda Castrodad

    BRENDA CASTRODAD

    Director of Human Resources

    A seasoned executive, Ms. Castrodad brings a wealth of experience in leading organizational development in start-ups and Fortune 500 companies within the life sciences sector. Most recently, Ms. Castrodad led the HR department at TissueTech, Inc., a Miami, FL-based biotech leader in regenerative amniotic tissue-based products, where she was responsible for transformation and automation of the company’s HR practices, talent planning, and team building. Prior to TissueTech, Inc., Ms. Castrodad spent six years at HeartWare, Inc., a heart failure medtech company acquired by Medtronic [NYSE:MDT] in 2016 for $1.1 billion. By optimizing the internal talent acquisition function and aligning business practices, Ms. Castrodad helped grow the organization from approx. 80 to 500+ staff which achieved approx. $250 million in revenues before the acquisition. Earlier in her career, Ms. Castrodad spent 16 years at Schering-Plough Corp, a pharmaceutical company acquired in 2009 for $41.1 billion by Merck & Co. [NYSE:MRK]. Ms. Castrodad holds a Master’s Degree in Public Administration and a Bachelor’s Degree in Social Sciences – Human Welfare from the University of Puerto Rico and a Labor Relations Certificate from the University of Michigan.

    Andrew Ballou

    ANDREW BALLOU

    Vice President, Investor Relations

    Mr. Ballou brings to BioSig over 25 years of experience in capital markets, including institutional equity sales and research analysis. Most recently, Mr. Ballou served as Managing Director, Head of Institutional Equity Sales at Janney Montgomery Scott LLC., a role in which he oversaw key accounts, including large multi-manager hedge funds, mutual funds and dedicated sector funds. Prior to that role Mr. Ballou managed selected key account coverage at RBC Capital Markets, including Millennium Partners, Soros Fund Management, SIR Capital, Columbia Threadneedle, Two Sigma Investments and Times Square Capital Management. During the course of his career Mr. Ballou analyzed various private and public companies in healthcare, media and retail sectors. Mr. Ballou graduated from Hampden-Sydney College, Virginia, with a Bachelor of Arts in English.

    DISCLAIMER

  • NEW OTC STOCK: Golden Grail Technology (GOGY)

    NEW OTC STOCK: Golden Grail Technology (GOGY)

    OUR NEW PROFILE IS:  GOGY

    TELL ME THAT THIS ISN’T ONE OF THE BEST CHARTS YOU HAVE SEEN IN 2022

    GOLDEN GRAIL TECHNOLOGY (OTC: GOGY) RECENTLY REDUCED THE NUMBER OF AUTHORIZED SHARES FROM 5 BILLION TO 500 HUNDRED MILLION

    GOLDEN GRAIL IS SET TO ANNOUNCE A NEW ADDITION TO THE PORTFOLIO IN EARLY DECEMBER OF THIS YEAR

    GOGY ANNOUNCES INCREASE IN DIRECT-TO-CONSUMER SALES FOR KOZ WATER

    LISTEN TO THE CEO OF GOGY ON THE STOCK DAY PODCAST 

    ________________________

    Hello Everyone,

    NEWS

    Golden Grail Technology (OTC: GOGY) grows headquarter location to accommodate growth of team and portfolio of brandsPR NEWSWIRE | 11/22/2022
    Golden Grail Technology (OTC: GOGY) Announcing Appointment of Lindsay Eshelman as COOPR NEWSWIRE | 11/03/2022
    Golden Grail Technology names new COOSEEKING ALPHA | 11/03/2022
    Golden Grail Technology (OTC: GOGY) announces increase in direct-to-consumer sales for KOZ WaterPR NEWSWIRE | 11/01/2022
    Golden Grail Technology (OTC: GOGY) Announces 2nd Production Run of Sketch Can by Tickle WaterPR NEWSWIRE | 10/07/2022
    Golden Grail Technology reduces authorized share count to 500MSEEKING ALPHA | 09/23/2022
    Golden Grail Technology (OTC: GOGY) announces reduction of authorized shares from 5 Billion to 500 Hundred MillionPR NEWSWIRE | 09/23/2022
    Golden Grail Technology (OTC: GOGY) Announcing Expansion Plan and Product Re-LaunchingPR NEWSWIRE | 09/20/2022

    Golden Grail Tech Beverages Announces Another Direct Sale – KOZ WaterPRESS RELEASE | 07/18/2022

    Golden Grail Tech Beverages Announces Strategic Sales Both Profitable and Purposeful – Cause WaterPRESS RELEASE | 07/15/2022
    Golden Grail Tech Beverages Announces Donating a Pallet of Trevi Essence Water to Boca Helping HandsPRESS RELEASE | 07/06/2022
    Golden Grail Tech Announces New Cause Water WebsitePRESS RELEASE | 06/28/2022
    Golden Grail Tech Declares Record Time from Acquisition to ProductionPRESS RELEASE | 06/21/2022
    Golden Grail Tech Beverages Announces Their Acquisition of KOZ WaterPRESS RELEASE | 06/14/2022
    Golden Grail Tech Beverages Announces Honoring World Ocean’s Day Through Community DonationPRESS RELEASE | 06/08/2022
    Golden Grail Tech Beverages Announces Tickle Water’s Sketch Can is in ProductionPRESS RELEASE | 06/07/2022
    Golden Grail Tech Beverages Announces Agreement with a Copacker for Sketch CanPRESS RELEASE | 06/01/2022
    Golden Grail Tech Beverages Announces New Formula for ‘Sketch Can’PRESS RELEASE | 05/24/2022
    Golden Grail Tech Beverages Announces a Production Run of Spider Energy DrinkPRESS RELEASE | 05/19/2022

    Source 1: https://www.zippia.com/advice/us-beverage-industry-statistics/
    Source 2: https://www.benzinga.com/trading-ideas/long-ideas/14/01/3014935/9-one-time-penny-stocks-didnt-stay-that-way
    Source 3: https://bit.ly/35F8adf
    Source 4: https://youtu.be/mpGg0lTgVVs
    Source 5: https://www.mydrinkbeverages.com/why-do-beverage-entrepreneurs-usually-fail
    Source 6: https://www.drinkticklewater.com/
    Source 7: https://tinyurl.com/48jbemav
    Source 8: https://www.drinktrevi.com/
    Source 9: https://spiderenergydrink.com/
    Source 10:  https://www.drinkscorpion.com/
    Source 11: https://www.goldengrailbeverages.com/#our-brands
    Source 12: https://finance.yahoo.com/news/golden-grail-successfully-launches-social-123000292.html
    Source 13: https://www.goldengrailbeverages.com/investor-hub
    Source 14: https://www.prnewswire.com/news-releases/united-states-kids-food–beverage-market-report-2021-growth-of-kids-fb-appears-to-be-outpacing-the-total-demand-for-traditional-food-and-beverages-301394374.html
    Source 15: https://gh.bmj.com/content/6/9/e007146

    THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
    OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY THE COMPANY GOLDEN GRAIL TECHNOLOGY (GOGY) FOR A ONE DAY GOGY AWARENESS CAMPAIGN.  WE HAVE PREVIOUSLY BEEN COMPENSATED A FEE OF FOUR THOUSAND USD FOR ONE PREVIOUS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
  • THESE 5 Penny Stocks READY TO EXPLODE! #1 SHORT SQUEEZE TOMORROW!

    THESE 5 Penny Stocks READY TO EXPLODE! #1 SHORT SQUEEZE TOMORROW!

    DON’T Miss Out On THESE!!! PGY Stock, PIK Stock, TBLT Stock, FAZE Stock, RDBX Stock, REV Stock, IMPP Stock, INDO Stock, HUSA Stock, DWAC Stock, BBIG Stock. This is what we do, Make our Subscribers Money in HOURS not years! 💥
    SIGN UP for FREEEEEE Alerts Here! https://viralstocks.io/signup/

    💥👇WATCH VIDEO HERE FOR OUR NEXT BIG PLAY!👇

    BOTTOM LINE

    As we keep saying, there are always opportunities in the markets and it’s our job to find winning penny stocks to buy. Huge gains can be made in such a short amount of time.

    It’s important to look for penny stocks that have yet to run. There are plenty of opportunities out there and we look at hundreds of penny stocks to buy each week trying to find the best alerts for our subscribers.

    Remember, all it takes is one or two to become a winner and you’ve crushed the market indices for the year.

    As always, good luck to all (except the shorts)!

    WHEN VIRAL STOCKS HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!

    Disclosure: We have no business relationship with any company whose stock is mentioned in this video. Viral Stocks is not an investment advisor and this video does not provide investment advice. Always do your own research, make your own investment decisions, or consult with your nearest financial advisor. This video is not a solicitation or recommendation to buy, sell, or hold securities. This video is our opinion and is meant for informational and educational purposes only and does not provide investment advice. Past performance is not indicative of future performance.

  • BBIG: ” TRIPLE DIGIT GAINS INCOMING!” NEXT Explosive MEME Stock!

    BBIG: ” TRIPLE DIGIT GAINS INCOMING!” NEXT Explosive MEME Stock!

    Viral Stocks recaps the price action in penny stocks on the NYSE and NASDAQ. DON’T Miss Out On THESE!!! VERU Stock, INDO Stock, IMPP Stock, CEI Stock, DWAC Stock, BBIG Stock. This is what we do, Make our Subscribers Money in HOURS not years!

  • #1 PENNY STOCK ASAP! Next EXPLOSIVE Stock is Here!

    #1 PENNY STOCK ASAP! Next EXPLOSIVE Stock is Here!

    Viral Stocks recaps the price action in penny stocks on the NYSE and NASDAQ. DON’T Miss Out On THESE!!! TNXP stock, SIGA stock, GOVX stock, and LOV stock.

    This is what we do, Make our Subscribers Money in HOURS not years! 💥

  • ALL IN ON THIS #1 SHORT SQUEEZE STOCK! + This Sector will make MILLIONAIRES!

    ALL IN ON THIS #1 SHORT SQUEEZE STOCK! + This Sector will make MILLIONAIRES!

    Viral Stocks recaps the price action in penny stocks on the NYSE and NASDAQ. DON’T Miss Out On THESE!!! RDBX Stock, MULN Stock, IMPP Stock, INDO Stock, HUSA Stock, DWAC Stock, BBIG Stock.

    This is what we do, Make our Subscribers Money in HOURS not years! 💥

  • Stocks with MASSIVE Short Squeeze Potential: APRN & EVFM

    Stocks with MASSIVE Short Squeeze Potential: APRN & EVFM

    Blue Apron Holdings, Inc. (NYSE: APRN) and Evofem Biosciences, Inc. (NASDAQ: EVFM) have been quickly climbing investors’ watchlists as an increasing short interest categorizes them as strong potential short-squeeze candidates. In this article, we analyze both stocks and their catalysts to determine if they could be profitable investments

    👇VIDEO Recap HERE!👇

    Short Squeeze Potential #1: APRN

    Ever since Blue Apron Holdings, Inc. (NYSE: APRN) introduced its seasonal meal kit to the market early last month, the stock has rebounded from a two-year low. Additionally, the stock continues to stir talks of a potential short squeeze among Reddit investors given its high short interest rate. Currently, APRN has a high short interest rate representing almost 31.8% of its float. With only 150,000 shares available to short, it is no surprise APRN is quickly showing major short squeeze potential.

     

    As a carbon-neutral meal-kit company, APRN has long focused on bringing incredible recipes to its customers. For a while now, the company has been experimenting with ways to grow its revenue. John Adler – the APRN’s VP of Culinary – previously highlighted APRN’s excitement to:

    feature this limited-time, seasonal meal-kits on an ongoing basis to provide our customers with everything they need to make entertaining easier, with minimal effort.”

    Now sold on Walmart’s website, Blue Apron’s new kit has been generating new buzz for the company after having struggled for the past 2 years to generate shareholder value. With the outbreak of COVID-19, the shift in consumer behavior urged more people to order takeout from food delivery services like DoorDash and Uber Eats – as many customers started to view meal kits as overpriced boxes of groceries.

    With this in mind, despite having generated $795 million in revenue by 2016, the company experienced major losses as a result of this shift. Even with a 2% revenue growth to $470 million last year, APRN’s net loss increased immensely from $46 million to $88 million.

    However, the future’s looking bright for APRN as CEO Lindley believes this new partnership with Walmart.com could be an “excellent way” to “introduce Blue Apron to new groups of customers who may not have considered a meal kit before.” With this in mind, the company plans on adding similar partnerships throughout the coming months in order to expand its direct-to-consumer business and stray away from its previous subscription-based model.

    Let’s take a deeper look at this stock…

    Following its recent run-up, APRN is currently trading at $4.79 with primary support at 3.57 and another at 2.68. The MACD is bullish to the upside and shows no signs of an incoming crossover. Similarly, the RSI is on an uptrend at 76 indicating APRN is slightly overbought but could continue its run-up soon.

    Given that it is currently trading at its resistance, bullish investors could secure a starter position on APRN and continue adding to that position as the price goes up – if the short squeeze comes to life. Despite its high short interest, APRN could be a profitable investment in the long term given the company’s plans to form more solid partnerships in the coming months. Get alerts on APRN and other top penny stock runners here.

    Short Squeeze Potential #2: EVFM

    Since its inception, Evofem Biosciences, Inc., (Nasdaq: EVFM) is known for developing and commercializing innovative products that are meant to address unmet needs in women’s sexual and reproductive health. As of June 30th, the company’s first FDA-approved product, Phexxi lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive – that is expected to provide protection into at least 2033.

    With this in mind, investors believed EVFM stands to benefit greatly from the Supreme court’s decision to overturn Roe v Wade – the 1970s ruling which recognized women’s right to undergo an abortion – driving a 200% increase in its PPS on June 27th. Given that 10 states have already moved to ban abortion, many are bullish Evofem’s non-hormonal birth control could be set for a surge in sales.

    Saundra Pelletier – EVFM’s CEO believes this patent and the development of the product could pave the way for major growth for the company in the coming months.

    This patent allowance is a clear nod to the innovation Phexxi brings to contraception and a woman’s ability to protect herself from unintended pregnancies.”

    EVFM continues to climb up the Fintel Gamma Squeeze List and is now standing at number 1 with high short interest of 17% – positioning it as a strong short squeeze candidate.

     

    Let’s analyze the stock’s technical indicators…

    EVFM Stock Chart

    Trading at $1.07, EVFM has resistance at 1.1166 and shows support at .903 and another at .3658. Accumulation has dropped significantly and continues to trend downwards while the MACD approaches a bearish crossover. The RSI is holding on near 52 – indicating the stock is currently stable to trade.

    While these indicators show an overall bearish sentiment, EVFM could see a rebound very soon if the short squeeze actually happens. Given its high short interest, investors are bullish that the short squeeze could happen soon pushing the stock past its current resistance. Get alerts straight to your inbox & be the first to know the top penny stock gainers.

  • EXPLOSIVE Biotech Stock! HUGE FDA NEWS! + RDBX 150% Short Interest?!

    EXPLOSIVE Biotech Stock! HUGE FDA NEWS! + RDBX 150% Short Interest?!

  • TOP BIOTECH STOCKS: ADPT, ALDX, ADTX

    TOP BIOTECH STOCKS: ADPT, ALDX, ADTX

    For the past couple of years, the biotech industry has seen a massive boom as an increasing number of biotechnology companies raced to develop treatments and vaccines for the COVID-19 virus. Among investors, the biotechnology market remains a hot market showing signs of major growth long-term. In this article, we discuss some of the hottest Biotech stocks investors are looking at right now – Adaptive Biotechnologies Corporation NASDAQ: ADPT, Aldeyra Therapeutics, Inc. NASDAQ: ALDX and 

    BIOTECH STOCK #1: ADPT

    The commercial-stage biotechnology company, Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is most known for its work to transform the genetics of the adaptive immune system into clinical products to diagnose and treat diseases.

    The company has been on investors’ radar ever since it launched the second test in its growing T-Detect franchise – T-Detect Lyme. By leveraging the body’s unique T-cell response to disease-associated antigens, T-Detect Lyme enables patients and healthcare providers to detect and diagnose early Lyme disease.

    An early diagnosis of Lyme disease enables treatment to stop its progression. But, today’s standard antibody tests could miss up to 75% of Lyme disease cases in the early phase of infection. 

    In a recent clinical study of patients with early Lyme disease, the T-cell test proved more accurate with almost 99% specificity than other leading antibody tests. The test also showed over 1.5 times greater sensitivity than standard two-tiered testing (STTT) in numerous patients. Given that Lyme disease is the most common tick-borne illness with an average 476 thousand Americans diagnosed and treated every year, this test is a breakthrough that could bring a plethora of growth opportunities for ADPT moving forward.

    Sharon Benzeno, Ph.D., chief commercial officer, immune medicine, Adaptive Biotechnologies seems bullish on the company’s future following the announcement: 

    The addition of T-Detect Lyme will support scaling clinical operations to enable our growing T-Detect portfolio, including testing in autoimmune disorders with high unmet need”

    Now trading at $8.73, ADPT has cooled off following its recent run-up which formed a new resistance at 9.21. The stock shows a support at 7.71 & 6.75. Accumulation has been on an upward trend but is recently declining. Similarly, the RSI was at 75 indicating the stock was overbought but has now cooled off near 57. Meanwhile, the MACD has shown a series of bullish crossover but is now on the verge of a bearish crossover.

    These indicators collectively show the stock losing its momentum following the run-up. The decline in accumulation could resemble the increasing number of investors cashing out for profits supported by a decreasing RSI reflecting the sell-out. Given that ADPT shows strong support at 7.71 & 6.75, bullish investors could wait for the RSI to regulate before finding a good entry point on this promising stock.

    BIOTECH STOCK #2: ALDX

    Since its inception, Aldeyra Therapeutics, Inc. NASDAQ: ALDX has been developing innovative therapies specifically designed to treat immune-mediated diseases. The company has been gaining attention mostly because of its two lead products – reproxalap and ADX-629 – which target systems-based mediators of inflammation: RASP (reactive aldehyde species). Currently in its late-stage clinical trials, Reproxalap targets patients with dry eye disease & allergic conjunctivitis. 

    As of recently, the company announced a new achievement in Phase 3 TRANQUILITY-2 clinical trial of reproxalap. According to the Schirmer test, a measure of ocular tear production and the dry eye disease objective sign most commonly utilized for drug approval – Reproxalap proved statistically superior to the vehicle for each of the two prespecified primary endpoints.

    With this in mind, Jacob R. Lang, O.D., F.A.A.O. – a dry eye disease specialist for Associated Eye Care in St. Paul – commented that:

    “Based on its rapid symptomatic control demonstrated across multiple clinical trials, reproxalap has the potential to be not only an important treatment option but a first-line therapy for dry eye disease.”

    Looking to the future, Todd C. Brady – President and CEO – highlighted the great impact of this achievement:

    For many of the more than 39 million U.S. adults who suffer from dry eye disease, we believe the need for a rapidly acting therapy with a novel mechanism of action is significant. We are confident in the potential of reproxalap to meet that need.”

    Ending the trading week on a high note, ALDX is trading at $3.67 with support near 3.18 and 3.04. Its massive run-up earlier this month formed a new resistance at 4. The MACD is bullish but seems poised for a bearish crossover. Meanwhile, accumulation is on an uptrend and the RSI is at 78 – indicating the stock is overbought.

    Considering these indicators, the stock could plummet to its support as the RSI cools off and investors cash out for profits. For this reason, bullish investors could wait for the indicators to regulate before finding a good entry point on this emerging biotech stock.

    BIOTECH STOCK #3: ADTX

    As a nation-leading advanced molecular diagnostics lab, Premier Medical Laboratory Services (PMLS) is fully certified by top laboratory accrediting organizations such as CLIA and COLA. Recently, the company announced it is adding AditxtScore to its growing menu of testing services.

    AditxtScore allows patients to know the protection level they have from an immune response to the virus or vaccination. Given that a large segment of the population has already undergone vaccination for COVID-19, AditxtScoreä is well-positioned to provide information on immune status during the ongoing phase of the pandemic.

    This could be crucial because while the virus continues to spread and the implications of the new variants are unknown, AditxtScoreä can be used to identify changes in immune response over time and contribute greatly to the continued understanding of responses to COVID-19 and its mutants.

    ADTX is currently trading at $.1560 near its support of .1393. It also shows a resistance near .2496 and .3004. Accumulation has been trending downwards but is recently seeing a slight uptick. The MACD is bullish and the RSI is at 58.

    The drop in accumulation could be the result of investors cashing out for profits following the run-up. However, the RSI continues to indicate the stock is slightly overbought. Investors bullish on the company’s latest announcement could find now a good entry point since the stock is trading near its support, or they could wait for the RSI to cool off to 50 before making an entry.